Inventiva S.A.

Inventiva S.A. için elimizdeki en son çeyrek

Şirketin kendi 6-K belgesinden.

Inventiva S.A. ne yapar

Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established. ​ 8 Cf press release of September 2, 2026. 9 Cf press release of April 22, 2026. 10 Cf press release of August 31, 2026. 11 Cf press release of July 8, 2026. pg. 4 ​ ​ ​

Şirketin kendi tanımı, açıklamanın sonunda göründüğü hâliyle.